Page 3 - Standard Deviation News Today

Abhishek Bhardwaj of Green Lantern Capital, states that India will continue to have high energy demand due to factors such as focus on manufacturing, which is more energy-intensive than the services sector. He also highlights that newer industries like AI-driven data centers contribute to this energy demand. Bhardwaj believes that the market is currently trading at an expensive valuation and faces challenges in sectors with high ownership and expectations, such as HDFC Bank. However, he sees opp...

Researchers investigated the association between cannabis, simulated driving, and concurrent blood tetrahydrocannabinol (THC) levels in older adults.

Analysis finds measures of iron deficiency, including ferritin, serum iron, and transferrin, were linked to an increased likelihood of depression in young adult males but not females.

A study of more than 140 adults with diabetes is providing additional insight into the prevalence of anemia among these patients as well as its association with changes in glycemic control.

The average of price targets set by Wall Street analysts indicates a potential upside of 42% in NIO Inc. (NIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at a 42.1% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 221.8% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Results of the phase 2 RISE UP trial offer additional perspective into the benefit-risk profile of mitapivat in patients with sickle cell disease.

Bezuclastinib, a targeted oral therapy, shows promise in reducing disease burden and improving symptoms by 50% or more in nonadvanced systemic mastocytosis patients, as revealed in the phase 2 SUMMIT trial data presented at ASH 2023.

A substudy of the ASCEND trial offers insight into the effects of omega-3 fatty acids use on risk of diabetic retinopathy in people with diabetes.